Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

 
• By Mandy Jackson

The company intends to seek US FDA approval in the first half of 2019 for its CGRP inhibitor and believes that liver toxicity previously associated with oral drugs in this class are not a problem for its candidate ubrogepant.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Clinical Trials

More from R&D